Mutations other than 103N in human immunodeficiency virus type 1 reverse transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure

Virology

Volumn 344, Issue 2, 2006, Pages 354-362

  Gatanaga, Hiroyuki ^a   Hachiya, Atsuko ^a   Kimura, Satoshi ^a   Oka, Shinichi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

HIV 1; K103R; Mutation; Non nucleoside reverse transcriptase inhibitor; Polymorphic; Resistance

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS ENZYME; ZIDOVUDINE;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS CULTURE; VIRUS INHIBITION; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

AMINO ACID SUBSTITUTION; CELL LINE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; SELECTION (GENETICS);

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 30044431689     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2005.09.005     Document Type: Article

References (26)

1. L.T. Bacheler Resistance to non-nucleoside inhibitors of HIV-1 Drug Resist. Updates 2 1999 56 67
2. V.W. Byrnes, V.V. Sardana, W.A. Schleif, J.H. Condra, J.A. Waterbury, J.A. Wolfgang, W.J. Long, C.L. Schneider, A.J. Schlabach, B.S. Wolanski, D.J. Graham, L. Gotlib, A. Rhodes, D.L. Titus, E. Roth, O.M. Blahy, J.C. Quintero, S. Staszewski, and E.A. Emini Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors Antimicrob. Agents Chemother. 37 1993 1576 1579
3. J.A. Collins, M.G. Thompson, E. Paintsil, M. Ricketts, J. Gedzior, and L. Alexander Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants J. Virol. 78 2004 603 611
4. P. Colson, M. Henry, C. Tourres, D. Lozachmeur, H. Gallais, J.A. Gastaut, J. Moreau, and C. Tamalet Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in southern France J. Clin. Microbiol. 42 2004 570 577
5. M. Cornelissen, R. van den Burg, F. Zorgdrager, V. Lukashov, and J. Goudsmit pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D J. Virol. 71 1997 6348 6358
6. E. De Clercq The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection Antiviral Res. 38 1998 153 179
7. H. Gatanaga, Y. Suzuki, H. Tsang, K. Yoshimura, M.F. Kavlick, K. Nagashima, R.J. Gorelick, S. Mardy, C. Tang, M.F. Summers, and H. Mitsuya Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors J. Biol. Chem. 277 2002 5952 5961
8. N. Gianotti, E. Boeri, M. Maillard, G. Serra, D. Ratti, G. Gallotta, D. Vacchini, Y. Tremolada, and A. Castagna In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results New Microbiol. 27 2004 111 117
9. A. Hachiya, S. Aizawa-Matsuoka, M. Tanaka, Y. Takahashi, S. Ida, H. Gatanaga, Y. Hirabayashi, A. Kojima, M. Tatsumi, and S. Oka Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 by using CCR5-expressing HeLa/CD4+ cell clone 1-10 (MAGIC-5) Antimicrob. Agents Chemother. 45 2001 495 501
10. A. Hachiya, S. Matsuoka-Aizawa, K. Tsuchiya, H. Gatanaga, S. Kimura, M. Tatsumi, and S. Oka "All-in-One Assay", a direct phenotypic anti-human immunodeficiency virus type 1 drug resistance assay for three-drug combination therapies that takes into consideration in vivo drug concentrations J. Virol. Methods 111 2003 43 53
11. A. Hachiya, H. Gatanaga, E. Kodama, M. Ikeuchi, M. Matsuoka, S. Harada, H. Mitsuya, S. Kimura, and S. Oka Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients Virology 327 2004 215 224
12. P.R. Harrigan, T. Mo, B. Wynhoven, J. Hirsch, Z. Brumme, P. McKenna, T. Pattery, J. Vingerhoets, and L.T. Bacheler Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors AIDS 19 2005 549 554
13. V.A. Johnson, F. Brun-Vezinet, B. Clotet, B. Conway, D.R. Kuritzkes, D. Pillay, J. Schapiro, A. Telenti, and D. Richman Update of the drug resistance mutations in HIV-1: 2005 Top. HIV Med. 13 2005 51 57
14. J.P. Kleim, M. Rosner, I. Winkler, A. Paessens, R. Kirsch, Y. Hsiou, E. Arnold, and G. Riess Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor specific (RT Leu-74→Val or Ile and Val-75→Leu or Ile) HIV-1 mutants Proc. Natl. Acad. Sci. U.S.A. 93 1996 34 48
15. E.I. Kodama, S. Kohgo, K. Kitano, H. Machida, H. Gatanaga, S. Shigeta, M. Matsuoka, H. Ohrui, and H. Mitsuya 4′-ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro Antimicrob. Agents Chemother. 45 2001 1539 1546
16. P. Kosalaraksa, M.F. Kavlick, V. Maroun, R. Le, and H. Mitsuya Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay J. Virol. 73 1999 5356 5363
17. J.H. Nunberg, W.A. Schleif, E.J. Boots, J.A. O'Brien, J.C. Quintero, J.M. Hoffman, E.A. Emini, and M.E. Goldman Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors J. Virol. 65 1991 4887 4892
18. M.E. Quinones-Mateu, J.L. Albright, A. Mas, V. Soriano, and E.J. Arts Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1 J. Virol. 72 1998 9002 9015
19. S.Y. Rhee, M.J. Gonzales, R. Kantor, B.J. Betts, J. Ravela, and R.W. Shafer Human immunodeficiency virus reverse transcriptase and protease sequence database Nucleic Acids Res. 31 2003 298 303
20. J.C. Schmit, J. Cogniaux, P. Hermans, C. Van Vaeck, S. Sprecher, B. Van Remoortel, W. Witvrouw, J. Balzarini, J. Desmyter, E. De Clercq, and A.M. Vandamme Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain J. Infect. Dis. 174 1996 962 968
21. M. Tanaka, R.V. Srinivas, T. Ueno, M.F. Kavlick, F.K. Hui, A. Fridland, J.S. Driscoll, and H. Mitsuya In vitro induction of human immunodeficiency virus type 1 variants resistant to 2′-beta-fluoro-2′,3′- dideoxyadenosine Antimicrob. Agents Chemother. 41 1997 1313 1318
22. A.M. Vandamme, A. Sonnerborg, M. Ait-Khaled, J. Albert, B. Asjo, L. Bacheler, D. Banhegyi, C. Boucher, F. Brun-Vezinet, R. Camacho, P. Clevenbergh, N. Clumeck, N. Dedes, A. De Luca, H.W. Doerr, J.L. Faudon, G. Gatti, J. Gerstoft, W.W. Hall, A. Hatzakis, N. Hellmann, A. Horban, J.D. Lundgren, D. Kempf, M. Miller, V. Miller, T.W. Myers, C. Nielsen, M. Opravil, L. Palmisano, C.F. Perno, A. Phillips, D. Pillay, T. Pumarola, L. Ruiz, M. Salminen, J. Schapiro, B. Schmidt, J.C. Schmit, R. Schuurman, E. Shulse, V. Soriano, S. Staszewski, S. Vella, M. Youle, R. Ziermann, and L. Perrin Updated European recommendations for the clinical use of HIV drug resistance testing Antiviral Ther. 9 2004 829 848
23. D.L. Winslow, S. Garber, C. Reid, H. Scarnati, D. Baker, M.M. Rayner, and E.D. Anton Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266 AIDS 10 1996 1205 1209
24. P.G. Yeni, S.M. Hammer, M.S. Hirsch, M.S. Saag, M. Schechter, C.C. Carpenter, M.A. Fischl, J.M. Gatell, B.G. Gazzard, D.M. Jacobsen, D.A. Katzenstein, J.S. Montaner, D.D. Richman, R.T. Schooley, M.A. Thompson, S. Vella, and P.A. Volberding Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel JAMA 292 2004 251 265
25. K. Yoshimura, R. Feldman, E. Kodama, M.F. Kavlick, Y.L. Qiu, J. Zemlicka, and H. Mitsuya In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues Antimicrob. Agents Chemother. 43 1999 2479 2483
26. S.D. Young, S.F. Britcher, L.O. Tran, L.S. Payne, W.C. Lumma, T.A. Lyle, J.R. Huff, P.S. Anderson, D.B. Olsen, S.S. Carroll, D.J. Pettibone, J.A. O'Brien, R.G. Ball, S.K. Balani, J.H. Lin, I.W. Chen, W.A. Schleif, V.V. Sardana, W.J. Long, V.W. Byrnes, and E.A. Emini L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase Antimicrob. Agents Chemother. 39 1995 2602 2605